Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Cytokinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 564

Market Cap: $6.5B

Website

Clinical Trials

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Omecamtiv mecarbil

First Posted Date: 2011-02-21

Last Posted Date: 2021-07-27

Lead Sponsor: Cytokinetics

Target Recruit Count: 614

Registration Number: NCT01300013

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Phase 2

Terminated

Conditions: Myasthenia Gravis

Interventions: Drug: Placebo
Drug: 250 mg CK-2017357
Drug: 500 mg CK-2017357

First Posted Date: 2010-12-30

Last Posted Date: 2019-09-24

Lead Sponsor: Cytokinetics

Target Recruit Count: 32

Registration Number: NCT01268280

Locations: 🇺🇸
UCSF - Fresno, Fresno, California, United States
🇺🇸
University of California - Irvine, Orange, California, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 12 locations

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Phase 2

Completed

Conditions: Intermittent Claudication
Peripheral Artery Disease

Interventions: Drug: Placebo
Drug: 375 mg CK-2017357
Drug: 500 mg CK-2017357

First Posted Date: 2010-05-26

Last Posted Date: 2019-05-14

Lead Sponsor: Cytokinetics

Target Recruit Count: 61

Registration Number: NCT01131013

Locations: 🇺🇸
Tatum Ridge Internal Medicine, Phoenix, Arizona, United States
🇺🇸
Apex Research Institute, Santa Ana, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

and more 11 locations

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: 250 mg CK-2017357
Drug: 500 mg CK-2017357

First Posted Date: 2010-03-18

Last Posted Date: 2019-05-10

Lead Sponsor: Cytokinetics

Target Recruit Count: 67

Registration Number: NCT01089010

Locations: 🇺🇸
Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
🇺🇸
University Neurology Associates, Fresno, California, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 12 locations

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Phase 2

Withdrawn

Conditions: Heart Failure

Interventions: Drug: Omecamtiv mecarbil

First Posted Date: 2010-02-26

Last Posted Date: 2021-07-30

Lead Sponsor: Cytokinetics

Registration Number: NCT01077167

Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: CK-1827452

First Posted Date: 2009-07-17

Last Posted Date: 2013-02-12

Lead Sponsor: Cytokinetics

Target Recruit Count: 35

Registration Number: NCT00941681

Locations: 🇬🇪
Cardio-Reanimation Centre, Tbilisi, Georgia
🇬🇪
Diagnostic Services Clinic, Tbilisi, Georgia
🇬🇪
Tbilisi State Medical University Clinic #1, Tbilisi, Georgia

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Drug: CK-1827452

First Posted Date: 2008-09-08

Last Posted Date: 2020-01-21

Lead Sponsor: Cytokinetics

Target Recruit Count: 2

Registration Number: NCT00748579

Locations: 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
🇺🇸
UUHSC / Division of Cardiology, Salt Lake City, Utah, United States
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Phase 2

Completed

Conditions: Angina Pectoris
Myocardial Ischemia
Heart Failure

Interventions: Drug: CK-1827452 48 mg and 11 mg iv infusion
Drug: CK-1827452 24mg and 6 mg iv infusion
Drug: CK-1827452 12.5mg capsule
Drug: CK-1827452 25mg capsule
Drug: Placebo iv infusion
Drug: Placebo capsule

First Posted Date: 2008-05-22

Last Posted Date: 2018-08-21

Lead Sponsor: Cytokinetics

Target Recruit Count: 94

Registration Number: NCT00682565

Locations: 🇬🇪
Tbilisi State Medical University Clinic #1, Tbilisi, Georgia
🇬🇪
Cardio-Reanimation Centre, Tbilisi, Georgia
🇬🇪
Cardiology Clinic, Tbilisi, Georgia

and more 11 locations

A Study of CK-1827452 Infusion in Stable Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: CK-1827452

First Posted Date: 2008-02-27

Last Posted Date: 2021-05-14

Lead Sponsor: Cytokinetics

Target Recruit Count: 45

Registration Number: NCT00624442

Locations: 🇺🇸
University of California, San Diego Medical Center, San Diego, California, United States
🇺🇸
Christiana Care Health Services, Inc., Newark, Delaware, United States
🇬🇪
Diagnostic Services Clinic, Tbilisi, Georgia

and more 14 locations

A Study of Ispinesib in Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Ispinesib

First Posted Date: 2008-02-06

Last Posted Date: 2019-05-06

Lead Sponsor: Cytokinetics

Target Recruit Count: 16

Registration Number: NCT00607841

Locations: 🇵🇪
Hospital Nacional Alberto Sabogal Sologúren, Lima, Peru
🇵🇪
Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
🇵🇪
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy